1
|
Capelle H, Tummino C, Greillier L, Gouitaa M, Birnbaum J, Ausias N, Barlesi F, Montana M. Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service. J Clin Pharm Ther 2017; 43:320-326. [PMID: 29092096 DOI: 10.1111/jcpt.12645] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2017] [Accepted: 10/10/2017] [Indexed: 11/27/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE With the increasing use of cancer chemotherapy agents, hypersensitivity reactions are commonly encountered. The allergic clinical symptoms are variable and unpredictable. The aim of this study was to identify the characteristics of hypersensitivity reactions and to assess the value of skin tests for platinum salts and pemetrexed in the treatment of patients with non-small cell lung cancers or malignant pleural mesothelioma. METHODS A single-centre retrospective study was performed for 2 years. Patients treated with the drugs of interest for an advanced or metastatic non-small cell lung cancers or malignant pleural mesothelioma and who experienced hypersensitivity reactions symptoms were eligible for this study. Clinical symptoms of hypersensitivity reactions, population characteristics and administered chemotherapy regimens were identified. RESULTS The hypersensitivity reactions frequency was rare (1.2%) and concerned 17 patients in our study. Typical clinical features of immediate hypersensitivity reactions associated with treatment were observed for nine patients (anaphylactic reactions for three cases, angioedema and hypotension associated with asthenia and heat in one case, respectively, and other cutaneous symptoms in the remaining four cases). Skin tests were positive in three patients, but only for platinum salts. The outcome after reintroduction of a negatively tested platinum salt allowed us to calculate a negative predictive value for platinum salt skin tests of 100%. For pemetrexed, skin tests were negative for all patients. WHAT IS NEW AND CONCLUSION Skin tests could be used to diagnose hypersensitivity reactions with platinum salts or to evaluate the possibility of cross-reactions between two platinum salts. A negative skin test may predict with reasonable reliability the absence of future hypersensitivity reactions in case of reintroduction of drug infusion. Because the IgE-mediated mechanism has never been demonstrated for pemetrexed, skin tests are not valid and have no diagnostic value for this molecule. Because hypersensitivity reactions are potentially fatal adverse events, we recommend that patients who experience a hypersensitivity reactions onset should be monitored closely and clinicians must be aware of hypersensitivity reaction signs.
Collapse
Affiliation(s)
- H Capelle
- Aix Marseille Univ, AP-HM, Oncopharma, Hôpital Nord, Marseille, France
| | - C Tummino
- Aix Marseille Univ, AP-HM, Service de Pneumologie, Hôpital Nord, Marseille, France
| | - L Greillier
- Aix Marseille Univ, AP-HM, Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille, France
| | - M Gouitaa
- Aix Marseille Univ, AP-HM, Service de Pneumologie, Hôpital Nord, Marseille, France
| | - J Birnbaum
- Aix Marseille Univ, AP-HM, Dermatologie, Vénéréologie et Cancérologie Cutanée, Marseille, France
| | - N Ausias
- Aix Marseille Univ, AP-HM, Oncopharma, Hôpital Nord, Marseille, France
| | - F Barlesi
- Aix Marseille Univ, AP-HM, Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille, France
| | - M Montana
- Aix Marseille Univ, AP-HM, Oncopharma, Hôpital Nord, Marseille, France.,Aix Marseille Univ, AP-HM, Service de Pneumologie, Hôpital Nord, Marseille, France.,Aix Marseille Univ, AP-HM, Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille, France.,Aix Marseille Univ, AP-HM, Dermatologie, Vénéréologie et Cancérologie Cutanée, Marseille, France.,Aix Marseille Univ, CNRS, ICR, Marseille, France
| |
Collapse
|
3
|
Taylor RM, Sillerud LO. Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. Int J Nanomedicine 2012; 7:4341-52. [PMID: 22915856 PMCID: PMC3419513 DOI: 10.2147/ijn.s34381] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2012] [Indexed: 12/28/2022] Open
Abstract
Background and methods: Problems with the clinical management of prostate cancer include the lack of both specific detection and efficient therapeutic intervention. We report the encapsulation of superparamagnetic iron platinum nanoparticles (SIPPs) and paclitaxel in a mixture of polyethyleneglycolated, fluorescent, and biotin-functionalized phospholipids to create multifunctional SIPP-PTX micelles (SPMs) that were conjugated to an antibody against prostate-specific membrane antigen (PSMA) for the specific targeting, magnetic resonance imaging (MRI), and treatment of human prostate cancer xenografts in mice. Results: SPMs were 45.4 ± 24.9 nm in diameter and composed of 160.7 ± 22.9 μg/mL iron, 247.0 ± 33.4 μg/mL platinum, and 702.6 ± 206.0 μg/mL paclitaxel. Drug release measurements showed that, at 37°C, half of the paclitaxel was released in 30.2 hours in serum and two times faster in saline. Binding assays suggested that PSMA-targeted SPMs specifically bound to C4-2 human prostate cancer cells in vitro and released paclitaxel into the cells. In vitro, paclitaxel was 2.2 and 1.6 times more cytotoxic than SPMs to C4-2 cells at 24 and 48 hours of incubation, respectively. After 72 hours of incubation, paclitaxel and SPMs were equally cytotoxic. SPMs had MRI transverse relaxivities of 389 ± 15.5 Hz/mM iron, and SIPP micelles with and without drug caused MRI contrast enhancement in vivo. Conclusion: Only PSMA-targeted SPMs and paclitaxel significantly prevented growth of C4-2 prostate cancer xenografts in nude mice. Furthermore, mice injected with PSMA-targeted SPMs showed significantly more paclitaxel and platinum in tumors, compared with nontargeted SPM-injected and paclitaxel-injected mice.
Collapse
Affiliation(s)
- Robert M Taylor
- Department of Biochemistry and Molecular Biology, University of New Mexico, Albuquerque, NM 87131, USA.
| | | |
Collapse
|
4
|
Surendiran A, Balamurugan N, Gunaseelan K, Akhtar S, Reddy KS, Adithan C. Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study. Indian J Pharmacol 2011; 42:40-3. [PMID: 20606836 PMCID: PMC2885639 DOI: 10.4103/0253-7613.62412] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/30/2009] [Revised: 10/12/2009] [Accepted: 03/12/2010] [Indexed: 11/22/2022] Open
Abstract
Aims: This prospective study was designed to monitor and analyze the pattern of occurrence of adverse drug reactions (ADRs) to cisplatin-based chemotherapy regimen in the cancer ward of a tertiary care hospital. Materials and Methods: Cancer patients who received cisplatin-based cancer chemotherapy were monitored for adverse reactions. The collected reports were analyzed for demographic and drug details, causality, preventability and severity of adverse effects. Causality was assessed by the World Health Organization (WHO) causality assessment scale and Naranjo's Algorithm. Preventability and severity of ADRs were assessed by modified Schumock and Thornton scale, modified Hartwig and Siegel scale respectively. Results: Among 51 patients, 48 developed ADRs to cisplatin chemotherapy. The reactions observed were nausea, alopecia, anorexia, vomiting, taste alteration, diarrhea, constipation, tinnitus, and hypocalcaemia. The WHO causality assessment scale indicated 69% “possible” and 31% “probable” but no “certain” reactions. Naranjo's Algorithm showed 62% “probable” and 38% “possible” reactions. Most of the reactions belonged to the category of “not preventable”. Reactions like nausea and vomiting belonged to the category of “definitely preventable”. Modified Hartwig and Siegel scale of severity assessment showed that most of the reactions were of “mild level 1” severity except for vomiting, diarrhea and hypocalcaemia, which were of “moderate level 3” severity. Conclusion: Cisplatin-based chemotherapy has a high potential to cause adverse effects. Most of the reactions were of milder nature but not preventable. The common adverse effects such as nausea and vomiting were preventable, but reactions like hypersensitivity reactions and anaphylaxis were not predictable.
Collapse
Affiliation(s)
- A Surendiran
- Department of Pharmacology, JIPMER, Pondicherry, India
| | | | | | | | | | | |
Collapse
|
5
|
Hausmann OV, Gentinetta T, Bridts CH, Ebo DG. The basophil activation test in immediate-type drug allergy. Immunol Allergy Clin North Am 2009; 29:555-66. [PMID: 19563997 DOI: 10.1016/j.iac.2009.04.011] [Citation(s) in RCA: 65] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Diagnosis of drug allergy involves first the recognition of sometimes unusual symptoms as drug allergy and, second, the identification of the eliciting drug. This is an often difficult task, as the clinical picture and underlying pathomechanisms are heterogeneous. In clinical routine, physicians frequently have to rely upon a suggestive history and eventual provocation tests, both having their specific limitations. For this reason both in vivo (skin tests) and in vitro tests are investigated intensively as tools to identify the disease-eliciting drug. One of the tests evaluated in drug allergy is the basophil activation test (BAT). Basophils with their high-affinity IgE receptors are easily accessible and therefore can be used as indicator cells for IgE-mediated reactions. Upon allergen challenge and cross-linking of membrane-bound IgE antibodies (via Fc-epsilon-RI) basophils up-regulate certain activation markers on their surface such as CD63 and CD203c, as well as intracellular markers (eg, phosphorylated p38MAPK). In BAT, these alterations can be detected rapidly on a single-cell basis by multicolor flow cytometry using specific monoclonal antibodies. Combining this technique with in vitro passive sensitization of donor basophils with patients' serum, one can prove the IgE dependence of a drug reaction. This article summarizes the authors' current experience with the BAT in the diagnostic management of immediate-type drug allergy mediated by drug-specific IgE antibodies.
Collapse
Affiliation(s)
- Oliver V Hausmann
- Department of Allergology, Department of Rheumatology, Allergology and Clinical Immunology, Inselspital, Freiburgstrasse, University of Bern, Bern 3010, Switzerland.
| | | | | | | |
Collapse
|
6
|
Ebo DG, Hagendorens MM, Bridts CH, De Clerck LS, Stevens WJ. The basophil activation test in immediate drug allergy. Acta Clin Belg 2009; 64:129-35. [PMID: 19432025 DOI: 10.1179/acb.2009.022] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Diagnosis of drug allergy is not always straight forward for several reasons. First, a broad spectrum of drugs can elicit various immune-mediated diseases with distinct pathomechanism, secondly, although exact epitope identification is not mandatory for clinical diagnosis, the epitope that causes the reaction is frequently unknown, thirdly in vitro or in vivo test results might not be predictive of a clinical situation, and finally the gold standard or reference test for diagnosis, the drug challenge, is a complicated and sometimes dangerous endeavour. Upon challenge with specific allergens that cross-link membrane-bound IgE antibodies, basophils upregulate the expression of different activation markers such as CD63 and CD203c. These immunophenotypic alterations can be detected on a single-cell basis by multicolour flow cytometry using specific monoclonal antibodies in the basophil activation test (BAT). This review intends to summarise our current experience with the BAT in the diagnostic management of immediate-type allergy to drugs and related compounds that are generally (but not always) mediated by drug-specific IgE antibodies.
Collapse
Affiliation(s)
- D G Ebo
- Department of Immunology, Allergology and Rheumatology, University Hospital Antwerp, University Antwerp, Belgium
| | | | | | | | | |
Collapse
|
7
|
Couraud S, Planus C, Rioufol C, Mornex F. [Platinum salts hypersensitivity]. REVUE DE PNEUMOLOGIE CLINIQUE 2008; 64:20-26. [PMID: 18603175 DOI: 10.1016/j.pneumo.2008.06.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
It become usually after 4 to 8 courses of treatment. A long platin free interval is an increased risk of reaction. Clinical manifestations are various and can be separate in light to mild or severe reactions. Diagnose is retrospective with results of skin test. Prick test and IDR (using sequentially diluted platin salt and delayed reading) are the most available, essentially in case of acute reaction (<2h after injection of platin salt). IDR realized 30 min before injection of platin salt can be a good predictive test of hypersensitivity reaction. Management of this adverse effect depends on clinical manifestation: light to mild: careful re-introduction with a desensitization protocol; severe: no re-introduction. If it's necessary, careful replacement by another platin salt can be possible, eventually in accordance with results of IDR to all platinum salt.
Collapse
Affiliation(s)
- S Couraud
- Service de radiothérapie et oncologie, Centre hospitalier Lyon Sud, 165 Chemin du Grand-Revoyet, Pierre-Bénite cedex, France
| | | | | | | |
Collapse
|
10
|
Meurice J, Roche N. « La Revue des Maladies Respiratoires : l’aventure continue ». Rev Mal Respir 2007. [DOI: 10.1016/s0761-8425(07)91006-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|